Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the tre⦠read more
Healthcare
Biotechnology
2 years
USD
Exclusive to Premium users
$17.47
Price-0.66%
-$0.11
$914.044m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-
5y CAGR-$107.433m
-
1y CAGR-
3y CAGR-
5y CAGR-$2.35
-
1y CAGR-
3y CAGR-
5y CAGR$143.096m
$181.621m
Assets$38.525m
Liabilities$1.030m
Debt0.6%
-
Debt to EBITDA-$58.431m
-
1y CAGR-
3y CAGR-
5y CAGR